CD103+ DCs selectively drive iTreg differentiation through RA and TGF-β dependent process, since addition of inhibitors of RA production or TGF-β neutralizing antibody suppresses iTreg induction[79,80]. The gene discussed is TGFB1; the disease is rheumatoid arthritis.